INOVIO Pharmaceuticals, Inc., a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share.
January 20, 2021
· 5 min read